Targeting the JNK MAPK cascade for inhibition: Basic science and therapeutic potential

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1697, Issue 1-2, 2004, Pages 89-101

  Bogoyevitch, Marie A ^a,b   Boehm, Ingrid ^a   Oakley, Aaron ^a   Ketterman, Albert J ^c   Barr, Renae K ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b HeartSearch   (Australia)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

c Jun N terminal kinase; Cell permeable peptide; CEP 1347; Cephalon Incorporated library compound number 1347; ERK; Extracellular signal regulated kinase; IC50; JNK interacting protein; Peptide inhibitor; SP600125

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CEP 1347; ENZYME INHIBITOR; GLUTAMIC ACID; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN SERINE THREONINE KINASE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTHRITIS; BRAIN INJURY; BRAIN PROTECTION; BRAIN TOXICITY; CANCER INHIBITION; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE MODEL; DRUG EFFICACY; DRUG SPECIFICITY; DRUG UTILIZATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC ANALYSIS; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; KNOCKOUT GENE; LETHALITY; NERVE CELL NECROSIS; NONHUMAN; OBESITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; SEQUENCE ANALYSIS; STRESS; STROKE;

AMINO ACID SEQUENCE; ANIMALS; ANTHRACENES; CARBAZOLES; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; INDOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES;

ANIMALIA;

EID: 1542269020     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2003.11.016     Document Type: Conference Paper

References (101)

1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934.
2. Kyriakis J.M., Avruch J. pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly L-lysine. J. Biol. Chem. 265:1990;17355-17363.
3. Kyriakis J.M., Banerjee P., Nikolakaki E., Dai T., Rubie E.A., Ahmad M.F., Avruch J., Woodgett J.R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature. 369:1994;156-160.
4. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene. 18:1999;6087-6093.
5. Dérijard B., Hibi M., Wu I.-H., Barrett T., Su B., Deng T., Karin M., Davis R.J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 76:1994;1025-1037.
6. Gupta S., Campbell D., Dérijard B., Davis R.J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science. 267:1995;389-393.
7. Yang S.-H., Yates P.R., Whitmarsh A.J., Davis R.J., Sharrocks A.D. The Elk-1 ETS-domain transcription factor contains a mitogen-activated protein kinase targeting motif. Mol. Cell. Biol. 18:1998;710-720.
8. Chow C.W., Rincon M., Cavanagh J., Dickens M., Davis R.J. Nuclear accumulation of NFAT4 opposed by the JNK signaling pathway. Science. 278:1997;1638-1641.
9. 2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell. Biol. 21:2001;2743-2754.
10. Lei K., Davis R.J. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2432-2437.
11. Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Dérijard B., Davis R.J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:1996;2760-2770.
12. 2-terminal kinase are expressed in primary gial tumors. Cancer Res. 63:2003;250-255.
13. Sluss H.K., Han Z., Barrett T., Davis R.J., Ip Y.T. A JNK signal transduction pathway that mediates morphogenesis an immune response in Drosophila. Genes Dev. 10:1996;2745-2758.
14. Riesgo-Escovar J.R., Jenni M., Fritz A., Hafen E. The Drosophila Jun-N-terminal kinase is required for cell morphogenesis but not for DJun-dependent cell fate specification in the eye. Genes Dev. 10:1996;2759-2768.
15. Galcheva-Gargova Z., Dérijard B., Wu I.-H., Davis R.J. An osmosensing signal transduction pathway in mammalian cells. Science. 265:1994;806-808.
16. Su Y.-C., Treisman J.E., Skolnik E.Y. The Drosophila Ste20-related kinase misshapen is required for embryonic dorsal closure and acts through a JNK MAPK module on an evolutionarily conserved signaling pathway. Genes Dev. 12:1998;2371-2380.
17. Stronach B., Perrimon N. Activation of the JNK pathway during dorsal closure in Drosophila requires the mixed lineage kinase, slipper. Genes Dev. 16:2002;377-387.
18. Botella J.A., Baines I.A., Williams D.D., Goberhan D.C.I., Proud C.G., Wilson C. The Drosphila cell shape regulator c-Jun N-terminal kinase also functions as a stress-activated protein kinase. Insect Biochem. Mol. Biol. 31:2001;839-847.
19. Igaki T., Kanda H., Yamamoto-Goto Y., Kanuka H., Kuranaga E., Aigaki T., Miura M. Eiger, a TNF superfamily ligand that triggers the Drosophila JNK pathway. EMBO J. 21:2002;3009-3018.
20. Chen H.-W., Marinissen M.J., Oh S.-W., Chen X., Melnick M., Perrimon N., Gutkind J.S., Huo S.X. CKA, a novel multidomain protein, regulates the JUN N-terminal Kinase signal transduction pathway in Drosophila. Mol. Cell. Biol. 22:2002;1792-1803.
21. Stronach B.E., Perrimon N. Stress signaling in Drosophila. Oncogene. 18:1999;6172-6182.
22. Kawasaki M., Hisamoto N., Iino Y., Yamamoto M., Ninomiya-Tsuji J., Matsumoto K. A Caenorhabditis elegans JNK signal transduction pathway regulates coordinated movement via type-D GABAergic motor neurons. EMBO J. 18:1999;3604-3615.
23. Hilberg F., Aguzzi A., Howells N., Wagner E.F. c-Jun is essential for normal mouse development and hepatogenesis. Nature. 365:1993;179-181.
24. Wisdom R., Johnson R.S., Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999;188-197.
25. Palmada M., Kanwal S., Rutkoski N.J., Gustafson-Brwon C., Johnson R.S., Wisdom R., Carter B.D. c-Jun is essential for sympathetic neuronal death induced by NGF withdrawal but not by p75 activation. J. Cell Biol. 158:2002;453-461.
26. Passegue E., Jochum W., Behrens A., Ricci R., Wagner E.F. Jun B can substitute for c-Jun in mouse development and cell proliferation. Nat. Genet. 30:2002;158-166.
27. Behrens A., Haigh J., Mechta-Grigoriou F., Nagy A., Yaniv M., Wagner E.F. Impaired intervertebral disc formation in the absence of Jun. Development. 130:2003;103-109.
28. Zenz R., Scheuch H., Martin P., Frank C., Eferl R., Kenner L., Sibilia M., Wagner E.F. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev. Cell. 4:2003;879-889.
29. David J.P., Sabapathy K., Hoffmann O., Idarraga M.H., Wagner E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation dependent and -independent mechanisms. J. Cell. Sci. 115:2002;4317-4325.
30. Behrens A., Jochum W., Sibilia M., Wagner E.F. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene. 19:2000;2657-2663.
31. Tibbles L.A., Ing Y.L., Kiefer F., Iscove N., Woodgett J.R., Lassam N. MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3. EMBO J. 15:1996;521-533.
32. Yang D.D., Kuan C.-Y., Whitmarsh A.J., Rincon M., Zheng T.S., Davis R.J., Rakic P., Flavell R.A. Absence of excitotoxicity induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature. 389:1997;865-870.
33. + cells to Th1 cells requires MAP kinase JNK2. Immunity. 9:1998;575-585.
34. Dong C., Yang D.D., Wysk M., Whitmarsh A.J., Davis R.J., Flavell R.A. Defective T cell differentiation in the absence of Jnk1. Science. 282:1998;2092-2095.
35. Sabapathy K., Hu Y., Kallunki T., Schreiber M., David J.P., Jochum W., Wagner E.F., Karin M. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr. Biol. 9:1999;116-125.
36. Dong C., Yang D.D., Tournier C., Whitmarsh A.J., Xu J., Davis R.J., Flavell R.A. JNK is required for effector T-cell function but not for T-cell activation. Nature. 405:2000;91-94.
37. Chang L., Jones Y., Ellisman M.H., Goldstein S.B., Karin M. JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev. Cell. 4:2003.
38. Jimenez B., Volpert O.V., Reiher F., Chang L., Munoz A., Karin M., Bouck N. c-Jun N-terminal kinase activation is required for the inhibition of vascularization by thrombospondin-1. Oncogene. 20:2001;3443-3448.
39. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature. 420:2002;333-336.
40. Chu W.-M., Ostertag D., Li Z.-W., Chang L., Chen Y., Hu Y., Williams B., Perrault J., Karin M. JNK2 and IKKβ are required for activating the innate response to viral infection. Immunity. 11:1999;721-731.
41. Han Z., Chang L., Yamanishi Y., Karin M., Firestein G.S. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum. 46:2002;818-823.
42. Kuan C.Y., Yang D.D., Samanta Roy D.R., Davis R.J., Rakic P., Flavell R.A. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron. 22:1999;667-676.
43. Weston C.R., Wong A., Hall J.P., Goad M.E.P., Flavell R.A., Davis R.J. JNK initiates a cytokine cascade that causes Pax2 expression and closure of the optic fissure. Genes Dev. 17:2003;1271-1280.
44. 2- terminal kinase-2-deficient mice. Cancer Res. 61:2001;3908-3912.
45. 2-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 62:2002;1343-1348.
46. Kennedy N.J., Sluss H.K., Jones S.N., Bar-Sagi D., Flavell R.A., Davis R.J. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev. 17:2003;629-637.
47. Teng D.H., Perry W.L., Hogan J.K., Baumgard M., Bell R., Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R., Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R., Sexton D., Schroeder M., Su P.H., Swedlund B., Kyriakis J.M., Avruch J., Bartel P., Wong A.K., Tavtigian S.V.et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 57:1997;4177-4182.
48. Su G.H., Hilgers W., Shekher M.C., Tang D.J., Yeo C.J., Hruban R.H., Kern S.E. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res. 58:1998;2339-2342.
49. Yoshida B.A., Dubauskas Z., Chekmareva M.A., Christiano T.R., Stadler W.M., Rinker-Schaeffer C.W. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 59:1999;5483-5487.
50. Kim H.L., Vander Griend D.J., Yang X., Benson D.A., Dubauskas Z., Yoshida B.A., Chekmareva M.A., Ichikawa Y., Sokoloff M.H., Zhan P., Karrison T., Lin A., Stadler W.M., Ichikawa T., Rubin M.A., Rinker-Schaeffer C.W. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 61:2001;2833-2837.
51. 2-terminal kinase3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors. J. Hum. Genet. 46:2001;182-187.
52. Yamada S.D., Hickson J.A., Hrobowski Y., Vander Griend D.J., Benson D., Montag A., Karrison T., Huo D., Rutgers J., Adams S., Rinker-Schaeffer C.W. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 62:2002;6717-6723.
53. Chae K.S., Ryu B.K., Lee M.G., Byun D.S., Chi S.G. Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma. Eur. J. Cancer. 38:2002;2048-2057.
54. Chen N., She Q.-B., Bode A.M., Dong Z. Differential gene expression profiles in Jnk1- and Jnk2-deficient murine fibroblast cells. Cancer Res. 62:2002;1300-1340.
55. Kaneko M., Saito Y., Saito H., Matsumoto T., Matsuda Y., Vaught J.L., Dionne C.A., Angeles T.S., Glicksman M.A., Neff N.T., Rotella D.P., Kauer J.C., Mallamo J.P., Hudkins R.L., Murakata C. Neurotrophic 3,9-bis[(alkylthio)methyl]- and -bis(alkoxymethyl)-K-252a derivatives. J. Med. Chem. 40:1997;1863-1869.
56. Maroney A.C., Glicksman M.A., Basma A.N., Walton K.M., Knight E., Murphy C.A., Bartlett B.A., Finn J.P., Angeles T., Matsuda Y., Neff N.T., Dionne C.A. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J. Neurosci. 18:1998;104-111.
57. Saporito M.S., Hudkins R.L., Maroney A.C. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog. Med. Chem. 40:2002;23-62.
58. Wagner A.C.C., Mazzucchelli L., Miller M., Camoratto A.M., Goke B. CEP-1347 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis. Am. J. Physiol.: Gasterointest. Liver Physiol. 278:2000;G165-G172.
59. 2-terminal kinase-dependent pathway. Am. J. Respir. Crit. Care Med. 163:2001;152-157.
60. 2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells. J. Immunol. 2000;3222-3228.
61. Le S., Connors T.J., Maroney A.C. c-Jun N-terminal kinase specifically phosphorylates p66ShcA at Serine 63 in response to ultraviolet radiation. J. Biol. Chem. 276:2001;48332-48336.
62. Maroney A.C., Finn J.P., Connors T.J., Durkin J.T., Angeles T., Gessner G., Xu Z., Meyer S.L., Savage M.J., Greene L.A., Scott R.W., Vaught J.L. CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. 276:2001;25302-25308.
63. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., Anderson D.W. SP600125, and anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13681-13686.
64. Han Z., Boyle D.L., Chang L., Bennett B., Karin M., Yang L., Manning A.M., Firestein G.S. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108:2001;73-81.
65. Vincenti M.P., Brinckerhoff C.E. The potential of signal transduction inhibitors for the treatment of arthritis: is it all just JNK? J. Clin. Invest. 108:2001;181-183.
66. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., Copeland R.A., Magolda R.L., Scherle P.A., Trzaskos J.M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273:1998;18623-18632.
67. Salituro F.G., Germann U.A., Wilson K.P., Bemis G.W., Fox T., Su M.S.S. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. 6:1999;807-823.
68. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., Adams J.L. Inhibition of p38 MAP kinse as a therapeutic strategy. Immunopharmacology. 47:2000;185-201.
69. Tak P.P., Firestein G.S. NF-κB: a key role in inflammatory diseases. J. Clin. Invest. 107:2001;7-11.
70. Shin M., Yan C., Boyd D. An inhibitor of c-Jun amino terminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim. Biophys. Acta. 1589:2002;311-316.
71. Utsugi M., Dobashi K., Ishizuka T., Endou K., Hamuro J., Murata Y., Nakazawa T., Mori M. c-Jun N-terminal kinase negatively regulates lipopolysaccharide-induced IL-12 production in human macrophages: role of mitogen-activated protein kinase in glutathione redox regulation of IL-12 production. J. Immunol. 171:2003;628-635.
72. Meguro M., Nishimura F., Ohyama H., Takashiba S., Murayama Y., Matsushita S. Ligation of IFN-gamma-induced HLA-DR molecules on fibroblasts induces RANTES expression via c-Jun N-terminal kinase (JNK) pathway. Cytokine. 22:2003;107-115.
73. 2-terminal kinase mediates expression of connective tissue growth factor induced by transforming growth factor-beta1 in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 28:2003;754-761.
74. Javelaud D., Laboureau J., Gabison E., Verrecchia F., Mauviel A. Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing. J. Biol. Chem. 278:2003;24624-24628.
75. Grosch S., Tegeder I., Schilling K., Maier T.J., Niederberger E., Geisslinger G. Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. FASEB J. 17:2003;1316-1318.
76. Marques C.A., Keil U., Bonert A., Steiner B., Haass C., Muller W.E., Eckert A. Neurotoxic mechanisms caused by the Alzheimer's disease-linked swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. J. Biol. Chem. 278(30):2003;28294-28302.
77. Curran B.P., Murray H.J., O'Connor J.J. A role for c-Jun N-terminal kinase in the inhibition of long-term potentiaion by interleukin-1β and long-term depression in the rate dentate gyrus in vitro. Neuroscience. 118:2003;347-357.
78. Huang C., Rajfur Z., Borchers C., Schaller M.D., Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature. 424:2003;219-223.
79. Chauhan D., Li G., Hideshima T., Podar K., Mitsiades C., Mitsiades N., Munshi N., Kharbanda S., Anderson K.C. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 278:2003;17593-17596.
80. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 289:2000;1938-1942.
81. Gum R.J., McLaughlin M.M., Kumar S., Wang Z., Bower M.J., Lee J.C., Adams J.L., Livi G.P., Goldsmith E.J., Young P.R. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. 273:1998;15605-15610.
82. Feramisco J.R., Krebs E.G. Inhibition of cyclic AMP-dependent protein kinase by analogues of a synthetic peptide substrate. J. Biol. Chem. 253:1978;8968-8971.
83. Walsh D.A., Glass D.B. Utilization of the inhibitor protein of adenosine cyclic monophosphate-dependent protein kinase, and peptides derived from it, as tools to study adenosine cyclic monophosphate-mediated cellular processes. Methods Enzymol. 201:1991;304-316.
84. Dunn C., Wiltshire C., MacLaren A., Gillespie D.A. Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. Cell. Signal. 14:2002;585-593.
85. Holzberg D., Knight C.G., Dittrich-Breiholz O., Schneider H., Dorrie A., Hoffmann E., Resch K., Kracht M. Disruption of the c-JUN-JNK complex by a cell-permeable peptide containing the c-JUN δdomain induces apoptosis and affects a distinct set of IL-1-induced inflammatory genes. J. Biol. Chem. 278:2003;40213-40223.
86. Dickens M., Rogers J.S., Cavanagh J., Raitano A., Xia Z., Halpern J.R., Greenberg M.E., Sawyers C.L., Davis R.J. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science. 277:1997;693-696.
87. Whitmarsh A.J., Cavanagh J., Tournier C., Yasuda J., Davis R.J. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science. 281:1998;1671-1674.
88. Yasuda J., Whitmarsh A.J., Cavanagh J., Sharma M., Davis R.J. The JIP group of mitogen-activated protein kinase scaffold proteins. Mol. Cell. Biol. 19:1999;7245-7254.
89. Kelkar N., Gupta S., Dickens M., Davis R.J. Interaction of a mitogen-activated protein kinase signaling module with the neuronal protein JIP3. Mol. Cell. Biol. 20:2000;1030-1043.
90. Bonny C., Nicod P., Waeber G. IB1, a JIP-related nuclear protein present in insulin-secreting cells. J. Biol. Chem. 273:1998;1843-1846.
91. Mooser V., Maillard A., Bonny C., Steinmann M., Shaw P., Yarnall D.P., Burns D.K., Schorderet D.F., Nicod P., Waeber G. Genomic organization, fine-mapping, and expression of the human islet-brain 1 (IB1) -Jun-amino-terminal kinase interacting protein-1 (JIP-1) gene. Genomics. 55:1999;202-208.
92. Schoorlemmer J., Goldfarb M. Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase. J. Biol. Chem. 277:2002;49111-49119.
93. Ito M., Yoshioka K., Akechi M., Yamashita S., Takamatsu N., Sugiyama K., Hibi M., Nakabeppu Y., Shiba T., Yamamoto K.-I. JSAP1, a novel Jun N-terminal protein kinase (JNK)-binding protein that functions as a scaffold factor in the JNK signaling pathway. Mol. Cell. Biol. 19:1999;7539-7548.
94. Fan M., Goodwin M., Vu T., Brantley-Finley C., Gaarde W.A., Chambers T.C. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J. Biol. Chem. 275:2000;29980-29985.
95. Bonny C., Oberson A., Negri S., Sauser C., Schorderet D.F. Cell-permeable inhibitors of JNK: novel blockers of β-cell death. Diabetes. 50:2001;77-82.
96. Barr R.K., Kendrick T.S., Bogoyevitch M.A. Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 277:2002;10987-10997.
97. Tanoue T., Adachi M., Moriguchi T., Nishida E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2:2000;110-116.
98. Chang C.I., Xu B.E., Akella R., Cobb M.H., Goldsmith E.J. Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol. Cell. 9:2002;1241-1249.
99. Becker-Hapak M., McAllister S.S., Dowdy S.F. TAT-mediated protein transduction into mammalian cells. Methods. 24:2001;247-256.
100. Bogoyevitch M.A., Kendrick T.S., Ng D.C.H., Barr R.K. Taking the cell by stealth or storm? Protein transduction domains (PTDs) as versatile vectors for delivery. DNA Cell Biol. 21:2002;879-894.
101. Manning A.M., Davis R.J. Targeting JNK for therapeutic benefit: from JUNK to gold. Nat. Rev., Drug Discov. 2:2003;554-565.